CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...
Combined healthy eating and exercise more effectively reduce harmful visceral fat, study showsWhen it comes to keeping that ...
CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors, today announced the publication of a ...
Aclipse Therapeutics LLC ("Aclipse" or "the Company") today announced that it has entered into a clinical collaboration and Know-How Agreement with Mayo Clinic for the Phase 2 clinical development of ...
Utilizing the gene-editing technology CRISPR, researchers have found a way to combat chemoresistance in lung cancer cells, restoring hope for patients. Shannon Horning/ SciTech Editor For patients ...
One of the biggest challenges in cancer treatment is something called “drug resistance.” This happens when cancer cells stop ...
A team of researchers from Academia Sinica and National Taiwan University has identified the Drosophila Cul2 substrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback